Piper Jaffray Companies upgraded shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) from a neutral rating to an overweight rating in a research note issued to investors on Wednesday, MarketBeat Ratings reports. The firm currently has $19.00 price target on the biopharmaceutical company’s stock.

Several other research firms have also commented on SGMO. Zacks Investment Research upgraded shares of Sangamo Therapeutics from a hold rating to a buy rating and set a $12.00 price target on the stock in a research report on Friday, August 18th. Jefferies Group LLC reiterated a buy rating and issued a $18.00 price target on shares of Sangamo Therapeutics in a research report on Thursday, September 14th. Wells Fargo & Company reiterated an outperform rating and issued a $30.00 price target (up from $20.00) on shares of Sangamo Therapeutics in a research report on Tuesday, September 5th. BidaskClub lowered shares of Sangamo Therapeutics from a buy rating to a hold rating in a research report on Friday, July 28th. Finally, ValuEngine upgraded shares of Sangamo Therapeutics from a sell rating to a hold rating in a research report on Friday, August 11th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the stock. Sangamo Therapeutics presently has an average rating of Buy and an average price target of $17.40.

Shares of Sangamo Therapeutics (NASDAQ SGMO) traded up $0.03 on Wednesday, reaching $14.63. 1,087,487 shares of the company’s stock traded hands, compared to its average volume of 1,296,826. Sangamo Therapeutics has a one year low of $2.65 and a one year high of $17.06. The company has a current ratio of 5.64, a quick ratio of 5.64 and a debt-to-equity ratio of 0.02.

Sangamo Therapeutics (NASDAQ:SGMO) last released its quarterly earnings results on Thursday, November 9th. The biopharmaceutical company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.19) by $0.04. The business had revenue of $11.81 million for the quarter, compared to analyst estimates of $10.37 million. Sangamo Therapeutics had a negative net margin of 157.66% and a negative return on equity of 31.81%. The company’s quarterly revenue was up 333.0% on a year-over-year basis. During the same period in the prior year, the business earned ($0.27) earnings per share. equities analysts anticipate that Sangamo Therapeutics will post -0.84 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: “Sangamo Therapeutics, Inc. (SGMO) Lifted to “Overweight” at Piper Jaffray Companies” was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of U.S. and international copyright and trademark law. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/11/18/sangamo-therapeutics-inc-sgmo-lifted-to-overweight-at-piper-jaffray-companies.html.

In other Sangamo Therapeutics news, VP Curt A. Herberts III sold 15,000 shares of the stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $15.25, for a total transaction of $228,750.00. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director William R. Ringo sold 31,000 shares of the stock in a transaction that occurred on Wednesday, September 20th. The stock was sold at an average price of $14.37, for a total transaction of $445,470.00. Following the transaction, the director now directly owns 31,800 shares in the company, valued at approximately $456,966. The disclosure for this sale can be found here. Insiders have sold 61,000 shares of company stock worth $899,220 in the last three months. Insiders own 5.50% of the company’s stock.

A number of large investors have recently bought and sold shares of SGMO. Blair William & Co. IL raised its stake in Sangamo Therapeutics by 4.3% during the second quarter. Blair William & Co. IL now owns 12,100 shares of the biopharmaceutical company’s stock worth $106,000 after purchasing an additional 500 shares during the period. Aperio Group LLC purchased a new position in Sangamo Therapeutics during the second quarter worth approximately $108,000. Principal Financial Group Inc. raised its stake in Sangamo Therapeutics by 6.8% during the second quarter. Principal Financial Group Inc. now owns 12,978 shares of the biopharmaceutical company’s stock worth $114,000 after purchasing an additional 832 shares during the period. Quantbot Technologies LP purchased a new position in Sangamo Therapeutics during the third quarter worth approximately $118,000. Finally, Virtu KCG Holdings LLC purchased a new position in Sangamo Therapeutics during the second quarter worth approximately $124,000. 64.08% of the stock is currently owned by institutional investors.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy.

Analyst Recommendations for Sangamo Therapeutics (NASDAQ:SGMO)

Receive News & Stock Ratings for Sangamo Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics Inc. and related stocks with our FREE daily email newsletter.